Top Page
Fosun International
(0656)
Fosun International (0656) vs. iShares MSCI Hong Kong ETF (EWH)
Fosun International Business Overview & Revenue Model
Fosun International Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 181.59B | 192.14B | 198.20B | 182.43B | 161.29B | 136.74B |
| Gross Profit | 49.65B | 51.60B | 50.80B | 47.31B | 55.65B | 50.59B |
| EBITDA | 429.15M | 329.02M | 30.50B | 1.02B | 4.05B | 5.02B |
| Net Income | -4.41B | -4.35B | 1.38B | -831.80M | 10.08B | 8.00B |
Balance Sheet | ||||||
| Total Assets | 735.69B | 796.53B | 808.39B | 806.38B | 806.28B | 767.72B |
| Cash, Cash Equivalents and Short-Term Investments | 111.54B | 133.09B | 133.27B | 150.38B | 166.93B | 166.95B |
| Total Debt | 222.11B | 241.86B | 233.57B | 245.92B | 257.87B | 250.87B |
| Total Liabilities | 538.35B | 598.99B | 599.81B | 607.30B | 603.16B | 574.64B |
| Stockholders Equity | 118.14B | 118.10B | 124.94B | 120.73B | 131.00B | 127.81B |
Cash Flow | ||||||
| Free Cash Flow | 13.20B | 15.61B | -3.35B | -5.45B | -9.64B | 2.73B |
| Operating Cash Flow | 16.24B | 26.88B | 9.82B | 1.76B | -3.32B | 8.89B |
| Investing Cash Flow | -2.72B | -126.97M | 17.59B | 35.58B | -536.96M | 612.52M |
| Financing Cash Flow | -18.06B | -14.27B | -39.67B | -38.12B | -3.66B | 2.29B |
Fosun International Technical Analysis
Fosun International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $25.20B | 6.30 | 6.18% | 4.69% | 7.45% | 11.56% | |
72 Outperform | $361.01B | 5.84 | 7.65% | 5.04% | 2.45% | -0.36% | |
66 Neutral | $42.39B | 7.31 | 6.26% | 4.77% | ― | ― | |
64 Neutral | $198.40B | 25.65 | 1.42% | 4.05% | 1.93% | -65.62% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | HK$86.20B | 73.59 | 0.47% | 5.02% | 6.44% | -95.37% | |
42 Neutral | $39.10B | -8.15 | -3.65% | 0.41% | -8.93% | -698.78% |
Fosun International Corporate Events
Fosun Pharma has announced the first grant under its 2025 H Share RSU Scheme, reducing the number of grantees to 195 and the RSUs to 10,589,500 due to changes in eligible employees. This move is part of its strategic efforts to incentivize employees and align their interests with the company’s growth, reflecting Fosun Pharma’s ongoing commitment to enhancing shareholder value and operational efficiency.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun High Technology reported a decrease in revenue and profit for the first nine months of 2025, with total assets slightly increasing by 0.1% compared to the end of last year. The decline in profit is attributed to the performance of its subsidiary, Shanghai Yuyuan Tourist Mart, impacting the company’s financial standing and signaling challenges in maintaining growth.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Shanghai Yuyuan Tourist Mart, a subsidiary of Fosun International, reported a significant decline in financial performance for the nine months ending September 2025. The company’s revenue decreased by 21.33% compared to the previous year, and it recorded a substantial net loss attributable to shareholders, indicating challenges in its operations. This financial downturn could impact Fosun’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International Limited successfully passed an ordinary resolution at its extraordinary general meeting on October 23, 2025, approving the adoption of the 2025 H Share RSU Scheme for Fosun Pharma. This decision reflects the company’s strategic move to enhance its equity incentive plans, potentially strengthening its market position and aligning interests with stakeholders.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International has announced an extraordinary general meeting to approve the adoption of the 2025 H Share RSU Scheme for Fosun Pharma. This move is expected to enhance Fosun Pharma’s employee incentive program, potentially improving operational efficiency and aligning stakeholder interests with company performance.
The most recent analyst rating on (HK:0656) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International has announced a progress update regarding its disposal of equity interest in Guangzhou Taotall and potential subscription in Hangzhou Tianyuan. The new agreement, following a revised valuation report, adjusts the terms of sale and payment, impacting the financial arrangements for Fosun Joygo and other sellers. This move reflects Fosun’s strategic realignment and could influence its market positioning and stakeholder relations.
The most recent analyst rating on (HK:0656) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International’s indirect subsidiary, Fidelidade, has entered into an agreement to sell 40% of its shares and voting rights in Luz Saúde, S.A. to MEIF 7 for EUR310 million. Despite the sale, Fidelidade will retain a 59.86% stake, ensuring Luz Saúde remains a subsidiary. This transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, requiring notification and announcement. The sale price was determined through negotiations considering Luz Saúde’s future development, financial performance, and strategic benefits.
The most recent analyst rating on (HK:0656) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International Limited announced the completion of a capital increase in Fengrui Fluorine, with the transaction finalized on August 29, 2025. This strategic move allows Fosun to indirectly hold a 15.7895% stake in Fengrui Fluorine through Hainan Mining, potentially strengthening its position in the fluorine industry and enhancing its investment portfolio.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International Limited has announced the settlement of a dispute with Cainiao Smart Logistics Network Limited regarding the cancellation price of Cainiao shares held by its subsidiary, Stater Investment Holdings Limited. The agreed cancellation price is set at US$0.62 per share, totaling approximately US$349.79 million. This settlement allows Fosun to avoid protracted litigation, reduce legal costs, and maintain its reputation, enabling the company to focus on strategic priorities and business development.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International is a global innovation-driven consumer group with a diversified portfolio across health, happiness, and wealth sectors, leveraging its extensive global presence and technological innovation to provide high-quality products and services worldwide.
Fosun International’s interim results for the first half of 2025 show a decline in total revenue compared to the previous year, with notable decreases in the Happiness and Intelligent Manufacturing segments. Despite macroeconomic challenges, the company has maintained steady overseas revenue growth, driven by its focus on healthcare, consumption, and insurance industries. The group’s strategic emphasis on technology innovation and global asset portfolio has helped offset some domestic consumption weaknesses, positioning it favorably in the global market.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International’s subsidiary, Yuyuan, reported a significant decline in revenue and net profit for the first half of 2025, with revenue dropping by 30.68% and net profit plummeting by 94.50% compared to the same period last year. Despite these declines, Yuyuan saw a substantial increase in net cash flow from operating activities, rising by 70.97%, which may indicate improved operational efficiency or cost management.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun Pharma has proposed the adoption of the 2025 A Share Option Scheme and the 2025 H Share RSU Scheme, which are designed to improve corporate governance and establish a long-term incentive mechanism. These schemes aim to attract and retain talent, mobilize the enthusiasm of executives and employees, and align the interests of shareholders and the company’s core team. The proposed H Share RSU First Grant involves issuing 10,696,400 RSUs to 201 eligible employees, conditional upon the adoption of the H Share RSU Scheme, and is intended to be satisfied by treasury H Shares. This initiative reflects Fosun Pharma’s commitment to fostering long-term development and enhancing its competitive position in the industry.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
Fosun International’s subsidiary, Hainan Mining, has entered into a Capital Increase Agreement with Fengrui Fluorine and its existing shareholders. Hainan Mining will invest RMB300 million to acquire a 15.7895% stake in Fengrui Fluorine, enhancing Fosun’s portfolio in the mining sector. This transaction is classified as a discloseable transaction under the Hong Kong Listing Rules, requiring notification and announcement due to the applicable percentage ratios. The agreement includes shareholder rights and profit guarantees, with implications for Fosun’s strategic positioning and potential growth in the fluorine industry.
Fosun International Limited has announced that its board of directors will hold a meeting on August 27, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting could have significant implications for the company’s financial strategy and shareholder returns, potentially affecting its market positioning and investor confidence.